Jennifer Baker, MD

Dr. Jennifer Baker conducts translational and clinical research focused on precision treatment and improving oncologic outcomes in breast cancer. Her specific research interests include:

• evaluating how exercise exposure may alter breast cancer risk and/or effect outcomes of breast cancer therapy;
• tailoring the surgical management of breast cancer after neoadjuvant chemotherapy;
• standardizing how surgeons approach high risk breast lesions; and
• improving surgical technique and outcomes in nipple sparing mastectomy.

Baker JL, Muhsen S, Zabor EC, Stempel M, Gemignani ML. Does Lymph Node Status Prior to Neoadjuvant Chemotherapy Influence the Number of Sentinel Nodes Removed? Ann Surg Oncol. 2018 Nov 30. doi: 10.1245/s10434-018-7004-6. [Epub ahead of print]

Unkart JT, Baker JL, Hosseini A, Hoh CK, Wallace MS, Vera DR, Wallace AM. Comparison of Post-injection Site Pain Between Technetium Sulfur Colloid and Technetium Tilmanocept in Breast Cancer Patients Undergoing Sentinel Lymph Node Biopsy. Ann Surg Oncol. 2015 Dec;22 Suppl 3:S559-65. doi: 10.1245/s10434-015-4802-y. Epub 2015 Aug 15.

Baker JL, Schwab RB, Wallace AM, Madlensky L. Breast cancer in a RAD51D mutation carrier: case report and review of the literature. Clin Breast Cancer. 2015 Feb;15(1):e71-5. doi: 10.1016/j.clbc.2014.08.005. Epub 2014 Sep 23. Review. No abstract available.

Baker JL, Pu M, Tokin CA, Hoh CK, Vera DR, Messer K, Wallace AM. Comparison of [(99m)Tc]tilmanocept and filtered [(99m)Tc]sulfur colloid for identification of SLNs in breast cancer patients. Ann Surg Oncol. 2015 Jan;22(1):40-5. doi: 10.1245/s10434-014-3892-2. Epub 2014 Jul 29.

Weiss A, Tran V, Baker J, Farnaz H, Wallace AM, Chang D, Ojeda-Fournier H, Blair SL. Increased likelihood of mastectomy in human epidermal growth factor receptor 2-positive ductal carcinoma in situ. Am Surg. 2014 Oct;80(10):936-9.